- Home
- ERAS vs HRTX Comparison
ERAS vs HRTX Comparison
Compare ERAS & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- HRTX
- Stock Information
- Founded
- ERAS 2018
- HRTX 1983
- Country
- ERAS United States
- HRTX United States
- Employees
- ERAS N/A
- HRTX N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- HRTX Health Care
- Exchange
- ERAS Nasdaq
- HRTX Nasdaq
- Market Cap
- ERAS 348.4M
- HRTX 325.0M
- IPO Year
- ERAS 2021
- HRTX 1987
- Fundamental
- Price
- ERAS $1.36
- HRTX $1.93
- Analyst Decision
- ERAS Strong Buy
- HRTX Strong Buy
- Analyst Count
- ERAS 6
- HRTX 2
- Target Price
- ERAS $4.83
- HRTX $5.50
- AVG Volume (30 Days)
- ERAS 1.5M
- HRTX 2.1M
- Earning Date
- ERAS 05-13-2025
- HRTX 05-06-2025
- Dividend Yield
- ERAS N/A
- HRTX N/A
- EPS Growth
- ERAS N/A
- HRTX N/A
- EPS
- ERAS N/A
- HRTX N/A
- Revenue
- ERAS N/A
- HRTX $148,518,000.00
- Revenue This Year
- ERAS N/A
- HRTX $12.60
- Revenue Next Year
- ERAS N/A
- HRTX $13.66
- P/E Ratio
- ERAS N/A
- HRTX N/A
- Revenue Growth
- ERAS N/A
- HRTX 12.43
- 52 Week Low
- ERAS $1.01
- HRTX $1.04
- 52 Week High
- ERAS $3.45
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- ERAS 54.43
- HRTX 45.93
- Support Level
- ERAS $1.06
- HRTX $1.82
- Resistance Level
- ERAS $1.47
- HRTX $1.93
- Average True Range (ATR)
- ERAS 0.14
- HRTX 0.11
- MACD
- ERAS 0.02
- HRTX -0.00
- Stochastic Oscillator
- ERAS 70.65
- HRTX 56.76
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.